搡老女人多毛老妇女中国,日韩亚洲欧美中文高清在线,人妻少妇一区二区三区,色妞色综合久久夜夜,日本熟妇xxxx

Your Good Partner in Biology Research

  1. 首頁
  2. 試劑盒
  3. 酶聯(lián)免疫試劑盒
  4. Human heparin cofactor Ⅱ,HCⅡELISA Kit

Human heparin cofactor Ⅱ,HCⅡELISA Kit

  • 中文名稱：
    人肝素輔因子Ⅱ(HCⅡ)酶聯(lián)免疫試劑盒
  • 貨號：
    CSB-E09492h
  • 規(guī)格：
    96T/48T
  • 價格：
    ￥3600/￥2500
  • 其他：

產(chǎn)品詳情

  • 產(chǎn)品描述：
    人肝素輔因子Ⅱ(HCⅡ)酶聯(lián)免疫試劑盒（CSB-E09492h）為雙抗夾心法ELISA試劑盒，定量檢測血清、血漿、組織勻漿樣本中的SERPIND1含量。SERPIND1 是重要靶點。它屬于絲氨酸蛋白酶抑制劑家族，參與凝血、纖溶等生理過程的調(diào)控。研究聚焦其與疾病關(guān)聯(lián)機制，如在血栓性疾病等發(fā)生發(fā)展中的作用，探索通過干預它來調(diào)節(jié)相關(guān)生理過程，為治療相關(guān)疾病提供新思路。試劑盒檢測范圍為1.25 pg/mL-80 pg/mL，本試劑盒適用于基礎(chǔ)醫(yī)學研究，可兼容多種樣本類型，包括EDTA或肝素抗凝處理的血漿樣本，以及經(jīng)離心預處理的動物或人體組織勻漿，為探索HCⅡ在心血管疾病、凝血異?；蚋闻K代謝相關(guān)研究提供可靠工具。實驗操作基于標準ELISA流程，通過抗原 - 捕獲抗體 - 檢測抗體的特異性結(jié)合，結(jié)合酶標儀讀取吸光度值實現(xiàn)定量分析，實驗結(jié)果穩(wěn)定且重復性良好，可滿足體外實驗中對HCⅡ表達水平動態(tài)監(jiān)測的需求，例如藥物干預、基因編輯或病理模型中的分子機制研究。本品僅用于科研，不用于臨床診斷，產(chǎn)品具體參數(shù)及操作步驟詳見產(chǎn)品說明書。
  • 別名：
    D22S673 ELISA Kit; HC II ELISA Kit; HC-II ELISA Kit; HC2 ELISA Kit; HCF2 ELISA Kit; HEP2_HUMAN ELISA Kit; Heparin cofactor 2 ELISA Kit; Heparin cofactor II ELISA Kit; HLS2 ELISA Kit; Leuserpin 2 ELISA Kit; LS2 ELISA Kit; Protease inhibitor leuserpin 2 ELISA Kit; Protease inhibitor leuserpin-2 ELISA Kit; serine (or cysteine) proteinase inhibitor, clade D (heparin cofactor), member 1 ELISA Kit; Serpin D1 ELISA Kit; serpin peptidase inhibitor, clade D (heparin cofactor), member 1 ELISA Kit; SERPIND1 ELISA Kit; THPH10 ELISA Kit
  • 縮寫：
  • Uniprot No.：
  • 種屬：
    Homo sapiens (Human)
  • 樣本類型：
    serum, plasma, tissue homogenates
  • 檢測范圍：
    1.25 pg/mL-80 pg/mL
  • 靈敏度：
    0.312 pg/mL
  • 反應(yīng)時間：
    1-5h
  • 樣本體積：
    50-100ul
  • 檢測波長：
    450 nm
  • 研究領(lǐng)域：
    Others
  • 測定原理：
    quantitative
  • 測定方法：
    Sandwich
  • 精密度：
    Intra-assay Precision (Precision within an assay): CV%<8%
    Three samples of known concentration were tested twenty times on one plate to assess.
    Inter-assay Precision (Precision between assays): CV%<10%
    Three samples of known concentration were tested in twenty assays to assess.
  • 線性度：
    To assess the linearity of the assay, samples were spiked with high concentrations of human HCⅡ in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
    　SampleSerum(n=4)
    1:100Average %92
    Range %86-98
    1:200Average %95
    Range %91-100
    1:400Average %98
    Range %90-105
    1:800Average %95
    Range %89-100
  • 回收率：
    The recovery of human HCⅡspiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
    Sample TypeAverage % RecoveryRange
    Serum (n=5) 9692-102
    EDTA plasma (n=4)9590-100
  • 標準曲線：
    These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
    pg/mlOD1OD2AverageCorrected
    802.718 2.785 2.752 2.668
    402.239 2.143 2.191 2.107
    201.361 1.387 1.374 1.290
    100.758 0.742 0.750 0.666
    50.452 0.418 0.435 0.351
    2.50.227 0.219 0.223 0.139
    1.250.184 0.188 0.186 0.102
    00.085 0.083 0.084 　
  • 數(shù)據(jù)處理：
  • 貨期：
    3-5 working days

產(chǎn)品評價

靶點詳情

  • 功能：
    Thrombin inhibitor activated by the glycosaminoglycans, heparin or dermatan sulfate. In the presence of the latter, HC-II becomes the predominant thrombin inhibitor in place of antithrombin III (AT-III). Also inhibits chymotrypsin, but in a glycosaminoglycan-independent manner.; Peptides at the N-terminal of HC-II have chemotactic activity for both monocytes and neutrophils.
  • 基因功能參考文獻：
    1. Loss of Heparin Cofactor is associated with insulin resistance . PMID: 28502917
    2. The plasma level of alpha2M was found positively correlated, while HCII level was negatively correlated with higher vulnerability of carotid plaques. Both proteins were efficient in differentiating stable and vulnerable carotid plaques. These provide potential new targets for the research of carotid plaque vulnerability. Plasma alpha2M and HCII may be potential biomarkers for evaluation of the vulnerability of carotid ... PMID: 28087279
    3. We found that SERPIND1 may act as a potential oncogene in the development of ovarian cancer PMID: 27430660
    4. Molecular modelling of HCII 1-75 predicted those portions of the acidic extension that had been previously visualized in crystal structures, and suggested that an alpha-helix found between residues 26 and 36 stabilizes one found between residues 61-67. PMID: 23496873
    5. heparin co-factor II is a novel metastasis enhancer and may be used as a prognostic predictor for heparin treatment in non-small cell lung cancer PMID: 25130770
    6. In this study, we demonstrate a previously unknown role for HCII in host defense. PMID: 23656734
    7. HCII potentiates the activation of vascular endothelial cells and the promotion of angiogenesis in response to hindlimb ischemia via an AMPK-eNOS signaling pathway. PMID: 22904320
    8. Plasma heparin cofactor II activity was independently and inversely associated with the development of cardiac remodeling, including cardiac concentric change, left atrial enlargement and left ventricular diastolic dysfunction. PMID: 21107326
    9. [REVIEW]HCII protects against vascular remodeling, including atherosclerosis PMID: 20671370
    10. potential for oversulfated disaccharides in controlling HCII-regulated thrombin generation PMID: 20053992
    11. Aspartic acid residues 72 and 75 and tyrosine-sulfate 73 of heparin cofactor II promote PMID: 11856753
    12. role of basic amino acids of the A helix of heparin cofactor II in heparin- or dermatan sulfate-mediated thrombin inhibition. PMID: 12095635
    13. Altering heparin cofactor II at VAL439 (P6) either impairs inhibition of thrombin or confers elastase resistance. PMID: 12152684
    14. The interactions of HCII with various heparins in solution competition experiments using SPR show that while calcium enhances this interaction, the activity of heparin-HCII complex against thrombin is not calcium dependent but can be enhanced by it. PMID: 15247982
    15. An asymptomatic Glu428Lys mutation affecting a conserved glutamate at the hinge (P17) of the reactive loop confirms the key structural role of the P17 glutamate in serpins. PMID: 15337701
    16. after receiving stent for peripheral artery disease, patients with a high HCII activity had a 0.39-fold reduced risk for instent restenosis PMID: 15543340
    17. HCII activity increases during pregnancy, and HCII levels are significantly decreased in women with severe pre-eclampsia. PMID: 16339402
    18. Plasma heparin cofactor II activity is an independent predictor of future cardiovascular events in patients after acute myocardial infarction. PMID: 18971786
    19. These results suggest that HCII is in a position to inhibit thrombin in atherosclerotic lesions where thrombin can exert a proatherogenic inflammatory response. PMID: 19747479

    顯示更多

    收起更多

  • 相關(guān)疾?。?/div>
    Thrombophilia due to heparin cofactor 2 deficiency (THPH10)
  • 蛋白家族：
    Serpin family
  • 組織特異性：
    Expressed predominantly in liver. Also present in plasma.
  • 數(shù)據(jù)庫鏈接：

    HGNC: 4838

    OMIM: 142360

    KEGG: hsa:3053

    STRING: 9606.ENSP00000215727

    UniGene: Hs.474270